Omalizumab Beats OIT in First Head-to-Head Multi-Food Allergy Trial: Daily Dose
Your daily dose of the clinical news you may have missed.
Delgocitinib Cream Shows "Super Response" in Chronic Hand Eczema: Daily Dose
OX40 Inhibitor Rocatinlimab Found Effective for Atopic Dermatitis: Daily Dose
Does it Itch? Is it Painful? Is it Dry? Dermatoses Symptoms Don't Lie
Raj Chovatiya, MD, PhD, MSCI, actually said symptoms "never" lie so, particularly in patients with skin of color, if skin signs aren't clear, ask about the patient's experience.
Does Skin Tone Affect Efficacy of Therapy for Atopic Dermatitis? Probably Not
AAD 2025: Raj Chovatiya, MD, PhD, MSCI, well-known physician scientist, says underrepresentation in clinical trials of those with skin of color precludes an evidence-based answer.
The Exposome is Everything in Atopic Dermatitis: An Expert Perspective on AD Pathophysiology
Raj Chovatiya, MD, PhD, MSCI, discusses the complex and widely variable influences that affect the manifestations and burden of atopic dermatitis across populations.
Melanin Isn't Everything: Skin Physiology Does Not Conform to Socially Defined Variables, Explains Raj Chovatiya, MD, PhD, MSCI
AAD 2025: Chovatiya discusses whether melanin concentration plays a role in skin physiology and cautioned against typing with factors that are not true biologic constructs.
Dupilumab Found Beneficial in COPD with Type 2 Inflammation: Daily Dose
Roflumilast Cream Shows Strong Tolerability in Patients with AD Failing Other Topicals: Daily Dose
What We Mean When We Say "Skin of Color" in Dermatology: A Closer Look with Raj Chovatiya, MD, PhD, MSCI
Chovatiya, expert clinical dermatologist and researcher, points out that the term "skin of color" comprises a heterogenous set of topics, in an interview at AAD 2025.
Managing Atopic Dermatitis in Special Populations: Expert Insights for Primary Care
In an interview at AAD 2025, Katrina Abuabara, MD, stressed the importance of collaboration between primary care physicians and dermatologists.
Antihistamines Are a Poor Option to Treat Eczema in Older Adults: Clinical Pearl
Antihistamines for itch caused by disorders like atopic dermatitis pose more problems, like sedation and fall risk, than they provide relief, according to Daniel Butler, MD.
Emergence of Trichophyton Indotineae: A Call for Culture-Driven Antifungal Therapy
Elizabeth Swanson, MD, shares how the rise of T.indotineae, a terbinafine-resistant fungal species, has shifted her treatment approach.
Epinephrine Nasal Spray Shows Rapid Symptom Relief in Children: Daily Dose
Daniel Butler, MD, a Leader in Geriatric Dermatology, Says Focus on the Overlap in the Etiology of Itch in Older Adults
AAD 2025: Tracing the multiple pathways that contribute to chronic itch vs looking for a singular cause helps optimize choice of therapy, Butler says.
Rethinking Shingles in Children: Expert Insights for Primary Care
Shingles is increasingly being observed in healthy, immunocompetent children. Elizabeth Swanson, MD, discusses how to recognize and respond.
Measles Resurgence and Vaccine Efficacy: A Conversation with Elizabeth Swanson, MD
Dr Swanson discusses the resurgence of measles and emphasizes the safety and efficacy of the measles vaccine.
Upadacitinib Demonstrates Superior Regional, Overall Efficacy vs Dupilumab in Atopic Dermatitis: Level Up Phase 3b/4 Trial Findings
Dupilumab-treated participants with recalcitrant head and neck symptoms who were switched to upadacitinib rapidly reached EASI 75 and steadily improved, among other findings.
Dupilumab Cuts Food Allergy IgE Levels in Small Study: Daily Dose
Hand, Foot, and Mouth Disease Update: A Conversation with Elizabeth Swanson, MD
Elizabeth Swanson, MD, discusses the changing face of HFMD, focusing on the increasingly prevalent coxsackievirus A6 strain and its unique characteristics
